Correlation Between Prime Medicine, and Immix Biopharma

Can any of the company-specific risk be diversified away by investing in both Prime Medicine, and Immix Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Prime Medicine, and Immix Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Prime Medicine, Common and Immix Biopharma, you can compare the effects of market volatilities on Prime Medicine, and Immix Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Prime Medicine, with a short position of Immix Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Prime Medicine, and Immix Biopharma.

Diversification Opportunities for Prime Medicine, and Immix Biopharma

-0.58

Correlation Coefficient

Prime Medicine,  Immix Biopharma

Excellent diversification

The 3 months correlation between Prime and Immix is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Prime Medicine, Common and Immix Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immix Biopharma and Prime Medicine, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Prime Medicine, Common are associated (or correlated) with Immix Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immix Biopharma has no effect on the direction of Prime Medicine, i.e., Prime Medicine, and Immix Biopharma go up and down completely randomly.

Pair Corralation between Prime Medicine, and Immix Biopharma

Given the investment horizon of 90 days Prime Medicine, Common is expected to under-perform the Immix Biopharma. But the etf apears to be less risky and, when comparing its historical volatility, Prime Medicine, Common is 1.35 times less risky than Immix Biopharma. The etf trades about -0.04 of its potential returns per unit of risk. The Immix Biopharma is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  156.00  in Immix Biopharma on September 27, 2024 and sell it today you would earn a total of  62.00  from holding Immix Biopharma or generate 39.74% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Prime Medicine, Common  vs.  Immix Biopharma

Prime Medicine, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Prime Medicine, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Etf's primary indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the fund shareholders.

Immix Biopharma

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Immix Biopharma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Immix Biopharma showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Prime Medicine, and Immix Biopharma

The main advantage of trading using opposite Prime Medicine, and Immix Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Prime Medicine, position performs unexpectedly, Immix Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immix Biopharma will offset losses from the drop in Immix Biopharma's long position.

The idea behind Prime Medicine, Common and Immix Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.